Actemra (Tocilizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Actemra (Tocilizumab) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the rising prevalence of autoimmune diseases, the increasing adoption of biologic therapies, growing awareness about chronic inflammatory conditions, strong regulatory approvals in key markets, and expanding healthcare infrastructure in developed regions.

Market growth during the forecast period is driven by the expansion of therapeutic applications, including COVID-19 cytokine release syndrome, a growing demand for personalized medicine, the development and adoption of biosimilars, rising healthcare expenditure in emerging markets, and increased awareness of biologic therapies in developing regions. Major trends in the forecast period include the increasing adoption of subcutaneous formulations, a focus on biosimilar development for cost reduction, advancements in biotechnology for enhanced drug delivery systems, ongoing clinical trials for new therapeutic indications, and strategic partnerships and investments by pharmaceutical companies.

The rising prevalence of rheumatoid arthritis is expected to propel the growth of the actemra (tocilizumab) market. Rheumatoid arthritis is a chronic autoimmune condition that leads to joint inflammation, damage, and reduced quality of life, affecting millions globally. Factors such as smoking, obesity, environmental exposures, and hormonal influences contribute to the rise in cases. Actemra (tocilizumab) works by inhibiting the interleukin-6 (IL-6) receptor, reducing inflammation, and preventing joint damage in patients who have not responded to other treatments. For instance, according to the National Institute for Health and Care Research (NIHR), approximately 700,000 people in the UK were living with rheumatoid arthritis in 2024. Additionally, in Australia, the Australian Institute of Health and Welfare reported that approximately 514,000 people were living with the condition in 2022. Therefore, the increasing prevalence of rheumatoid arthritis is expected to drive the growth of the actemra (tocilizumab) market.

A key trend in the actemra (tocilizumab) market is the development of biosimilars, which provide a more affordable alternative to the original drug. Biosimilars are approved to treat autoimmune diseases, offering similar efficacy to the originator drug, Actemra. For example, in November 2023, Fresenius Kabi launched Tyenne, the first tocilizumab biosimilar referencing RoActemra (tocilizumab) in the European Union. Tyenne is approved for treating multiple inflammatory and immune diseases, including rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome (CRS). This development is expected to increase market competition and provide more treatment options at lower costs.

In September 2024, Bio-Thera Solutions Ltd., a China-based biopharmaceutical company, partnered with Biogen Inc. to publish Phase 3 clinical trial data for TOFIDENCE (BAT1806/BIIB800), a biosimilar to Actemra. TOFIDENCE aims to expand treatment access for autoimmune conditions. Biogen Inc. is a US-based biotechnology company specializing in therapies for neurological and autoimmune diseases. This partnership is set to enhance the growth of the Actemra market by broadening treatment options and improving access to affordable therapies.

Major players operating in the actemra (tocilizumab) market are Roche Holding AG; Fresenius Kabi.

North America was the largest region in the actemra (Tocilizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in actemra (tocilizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the actemra (tocilizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Actemra (Tocilizumab) is a prescription biologic medication classified as an interleukin-6 (IL-6) receptor antagonist, used to treat various autoimmune and inflammatory conditions. It works by inhibiting IL-6, a cytokine involved in inflammation, which helps reduce symptoms and prevent disease progression in conditions such as rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome.

The primary product types of actemra (tocilizumab) are categorized by purity levels less than 98%, between 98% and 99%, and more than 99%. The less than 98% purity includes tocilizumab products that may have more impurities or residual components, potentially affecting efficacy and safety. The dosages available are injection, solution, and concentrate, with routes of administration including oral, parenteral, and others. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Actemra is used in various applications such as cytokine release syndrome (CRS), systemic juvenile idiopathic arthritis (SJIA), giant cell arteritis (GCA), and rheumatoid arthritis (RA).

The actemra (tocilizumab) market research report is one of a series of new reports that provides actemra (tocilizumab) market statistics, including actemra (tocilizumab) industry global market size, regional shares, competitors with a actemra (tocilizumab) market share, detailed actemra (tocilizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the actemra (tocilizumab) industry. This actemra (tocilizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The actemra (tocilizumab) market consists of sales of intravenous (IV) and subcutaneous (SC) formulations used to treat autoimmune and inflammatory diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.